Literature DB >> 7836739

Perturbed development of T and B cells in mice expressing an Hlx homeobox transgene.

J D Allen1, A W Harris, M L Bath, A Strasser, R Scollay, J M Adams.   

Abstract

Within the lymphoid compartment of mice, the Hlx homeobox gene is expressed only at early stages of B-lymphoid differentiation. To determine whether Hlx influences lymphopoiesis, transgenic mice were developed to enforce Hlx expression throughout the B and T cell lineages. The strain with the highest transgene expression in both cell types (Hlx-94) exhibited marked perturbations in both B and T cell development. In these mice, the thymus lacked almost all mature CD4+8- and CD8+4- cells and the medulla was greatly shrunken, whereas nearly one-half the T cells in the periphery were CD4+8+, a cell type normally confined to the thymus. The peripheral CD4+8+ cells had some features of mature T cells, including responsiveness to mitogens. Presumably these cells had emigrated prematurely from the thymus and generated mature T cells in the periphery. Bone marrow transplantation experiments indicated that the defects was intrinsic to the Hlx-94 hematopoietic cells rather than support cells. Although thymocyte development in Hlx-94 mice was blocked at the stage when selection normally occurs, analysis of lymphocyte populations in the progeny of crosses with mice transgenic for an anti-HY T cell receptor indicated that neither positive nor negative selection of T cells was markedly affected. In addition to T cell defects, Hlx-94 mice had subnormal numbers of B lymphoid cells in the bone marrow and spleen, and their surface phenotype suggested that B cell development after the pro-B stage was impeded. Furthermore, the B cell response to stimulation with LPS was impaired. These striking developmental defects suggest that the Hlx gene may help to govern lymphoid maturation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7836739

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The Functions and Mechanism of a New Oligopeptide BP9 from Avian Bursa on Antibody Responses, Immature B Cell, and Autophagy.

Authors:  Xiu Li Feng; Man Man Zong; Guang Fang Zhou; Yang Zheng; Yuan Nan Yu; Rui Bing Cao; Pu Yan Chen; Mei Yang
Journal:  J Immunol Res       Date:  2019-01-06       Impact factor: 4.818

Review 2.  Deregulated NKL Homeobox Genes in B-Cell Lymphoma.

Authors:  Stefan Nagel; Hans G Drexler
Journal:  Cancers (Basel)       Date:  2019-11-26       Impact factor: 6.639

3.  Establishment of the TALE-code reveals aberrantly activated homeobox gene PBX1 in Hodgkin lymphoma.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Roderick A F MacLeod; Hans G Drexler
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

4.  NKL Homeobox Gene VENTX Is Part of a Regulatory Network in Human Conventional Dendritic Cells.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Hans G Drexler
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

5.  Determination of endothelial stalk versus tip cell potential during angiogenesis by H2.0-like homeobox-1.

Authors:  Shane P Herbert; Julia Y M Cheung; Didier Y R Stainier
Journal:  Curr Biol       Date:  2012-08-23       Impact factor: 10.834

6.  A metabolic interplay coordinated by HLX regulates myeloid differentiation and AML through partly overlapping pathways.

Authors:  Indre Piragyte; Thomas Clapes; Aikaterini Polyzou; Ramon I Klein Geltink; Stylianos Lefkopoulos; Na Yin; Pierre Cauchy; Jonathan D Curtis; Lhéanna Klaeylé; Xavier Langa; Cora C A Beckmann; Marcin W Wlodarski; Patrick Müller; Dominic Van Essen; Angelika Rambold; Friedrich G Kapp; Marina Mione; Joerg M Buescher; Erika L Pearce; Alexander Polyzos; Eirini Trompouki
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

7.  Aberrant expression of NKL homeobox gene HLX in Hodgkin lymphoma.

Authors:  Stefan Nagel; Claudia Pommerenke; Corinna Meyer; Maren Kaufmann; Roderick A F MacLeod; Hans G Drexler
Journal:  Oncotarget       Date:  2018-02-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.